MENU
Go to the list of all blogs
published in Blogs
Jul 23, 2024

$MDGL, $EW, $SNY, $BSX Propel Cardiovascular Sector with Impressive +7.16% Weekly Performance Surge

The cardiovascular group within the medical device sector has displayed robust performance, witnessing a notable surge of +7.16% over the past week. This upturn has drawn attention to several key tickers driving this momentum: MDGLEWSNYBMYBSXCRMDATXS, and ARDX.

Positive Outlook & Volume Indicator

These stocks currently demonstrate a positive outlook, supported by the Volume Indicator and Tickeron's projections. Tickeron's analysis suggests a potential further increase of over 4.00% within the next month, with a likelihood of 69%. Moreover, the daily ratio of advancing to declining volumes stood at a promising 1.42 to 1 during the last month.

Stochastic Indicator & Positive Trends

The Stochastic indicator showcases a positive trend across 5 stocks within this group, boasting an average likelihood of 75%. This consistent upward trajectory adds weight to the optimistic outlook for these cardiovascular companies.

Market Capitalization Insights

Notably, the average market capitalization within this group stands at a substantial $43.2 billion. SNY holds the highest valuation at $118.8 billion, while ATXS is the lowest valued company at $171 million.

Price Movements

Recent price movements further underline this sector's strength. On average, weekly, monthly, and quarterly price growths for these stocks registered at 7.16%, 21.1%, and 15.58%, respectively. ARDX led the pack with a staggering 50.41% increase, while CRMD experienced a minor setback of -4.24%.

Highlights from Top Performers

  • Edwards Lifesciences (EW) demonstrated a robust +7.6% surge, solidifying its upward trend.
  • Sanofi ADS (SNY) experienced a significant +6.19% increase, also contributing to the group's positive momentum.
  • Boston Scientific (BSX) recorded a commendable +5.5% jump, reinforcing the overall bullish sentiment in the sector.

Volume Analysis

The group exhibited substantial volume growth, with an average weekly increase of 69.1%. Monthly and quarterly volume growths averaged at 49.93% and 195.64%, respectively. Noteworthy spikes in volume were observed for Astria Therapeutics and Ardelyx stocks, leading to record-breaking daily growth percentages.

Individual Stock Insights

  1. MDGL: Recent data indicates a potential shift from an upward trend to a downward one, with the RSI Oscillator moving out of the overbought zone. Tickeron's analysis suggests a 90% likelihood of a downward move in the days ahead.

  2. EW: Despite a recent downtrend, indicators point to a potential reversal as the price broke its lower Bollinger Band. This could signal a move towards the middle band, with a 73% chance of an upward trend.

  3. SNY: The stock has transitioned from a downward to an upward trend by crossing its 50-day Moving Average. Past instances indicate a 62% probability of continued upward movement.

In summary, the cardiovascular group within the medical device sector has experienced a robust surge, backed by positive indicators and strong performances from key players like EWSNY, and BSX. While individual stocks might exhibit varied trends, the overall outlook remains optimistic, suggesting potential further growth in the near term.

Related Ticker: MDGL, EW, SNY, BMY, BSX, CRMD, ATXS, ARDX

MDGL in upward trend: price rose above 50-day moving average on October 31, 2024

MDGL moved above its 50-day moving average on October 31, 2024 date and that indicates a change from a downward trend to an upward trend. In of 49 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2024. You may want to consider a long position or call options on MDGL as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 10-day moving average for MDGL crossed bullishly above the 50-day moving average on November 04, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 23 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for MDGL moved out of overbought territory on November 13, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MDGL broke above its upper Bollinger Band on October 31, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MDGL entered a downward trend on October 30, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.842) is normal, around the industry mean (14.905). P/E Ratio (0.000) is within average values for comparable stocks, (98.894). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.944). MDGL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (84.746) is also within normal values, averaging (217.940).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.77B. The market cap for tickers in the group ranges from 151 to 473.6B. NONOF holds the highest valuation in this group at 473.6B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 6%. CERO experienced the highest price growth at 194%, while ABIO experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 71% and the average quarterly volume growth was 231%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 57
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
BMY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceuticals products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Route 206 and Province Line Road
Phone
+1 609 252-4621
Employees
34100
Web
https://www.bms.com